Pathological evaluation of bladder cancer typically reveals great tumour heterogeneity, and therefore the common observation of urothelial carcinoma exhibiting a wide variety of histopathological patterns is not surprising. Some of these patterns are so distinctive that they have been recognised as specific variants of urothelial carcinoma. Classifications have recently been revised in the 2016 World Health Organisation (WHO) classification of tumours of the urinary system and male genital organs. The current WHO classifications clarify terminological issues and provide better definition criteria, but also incorporate some new entities. Many of these variants have important prognostic or therapeutic implications worth knowing by the urologist and oncologist, but also represent diagnostic challenges in daily pathology practice. This review will discuss the features of variants of urothelial carcinoma in the context of our current clinical practice. Histological variations and new entities of bladder cancer not included in the current WHO classification of urothelial tumours will be briefly discussed.
Introduction
Urothelial carcinoma has a propensity for divergent differentiation. Virtually the entire spectrum of bladder cancer variants described below may be seen, in variable proportions, in otherwise conventional urothelial carcinoma or in its pure forms (Table 1) . [1] [2] [3] [4] [5] [6] [7] [8] Despite pathological criteria being described for most of these variants, the diagnosis remains challenging in daily practice, a fact that frequently requires consultation with a specialised genitourinary pathologist. [1] [2] [3] [4] [5] [6] [7] [8] However, some variants may be under-recognised or misclassified due to evolving inclusion criteria for diagnosis and the frequent interobserver variability. [1] [2] [3] [4] [5] [6] [7] [8] The use of differentially expressed immunohistochemical markers acting as ancillary tests to confirm variant diagnosis will probably reduce interobserver variability in daily practice. An additional confounding factor can be found in a subset of patients in whom multiple variant patterns may occur concurrently and at differing proportions, due probably to a process of dedifferentiation such as that observed in other organs. The phenotype of these histological variants probably reflects underlying diversity in molecular composition. [9] [10] [11] [12] In recent years, improved pathological recognition and clinical understanding of these entities opened a novel paradigm in bladder cancer management based on the current understanding of how distinct variant categories can affect patient prognosis; this novel approach has impacted the process of therapy selection. [13] [14] [15] [16] [17] [18] [19] [20] Thus, the identification of urothelial carcinoma with variant histology has important clinical implications because misdiagnosis may result in improper or unnecessarily aggressive treatment. 8 Overall, histological variants follow a more aggressive clinical course than conventional urothelial carcinoma, but conclusive data on their effect on survival are currently lacking.
The recently released 2016 World Health Organisation (WHO) classification of tumours of the urinary system and male genital organs currently presents better definition criteria of pathological features useful in the establishment of a correct diagnosis, and updates the terminology and molecular characteristics of these important subtypes of bladder cancer ( Table 2) . 1 Herein, we describe the criteria for the histological diagnosis of variants of urothelial carcinoma, and highlight the critical features of each that are relevant to patient prognosis and the pathological and molecular features useful in differential diagnosis or with potential to guide therapy. Growth variations of urothelial carcinoma and new entities not included in the current WHO classification of tumours of the urinary tract are also briefly discussed (Table 3) .
Non-urothelial bladder cancer subtypes (including primary bladder adenocarcinoma, pure squamous cell carcinoma, pure small-cell carcinoma and urachal carcinoma) frequently referred to as bladder carcinoma with variant histology in the urological literature are beyond the scope of this review.
Urothelial Carcinoma With Divergent Differentiation
The most common urothelial carcinoma variant is known as urothelial carcinoma with divergent differentiation, which includes squamous, glandular, trophoblastic and other rare variations thereof (Table 1, Figure 1 ). Typically, divergent differentiation occurs in a background of conventional urothelial carcinoma. 1, 22 Overall, most clinicians treat urothelial carcinoma with divergent differentiation in the same manner as conventional urothelial carcinoma, as prognosis is generally thought to be similar, and current evidence has supported this approach. [13] [14] [15] [16] [17] [18] [19] [20] 
U R O T H E L I A L C A R C I N O M A W I T H S Q U A M O U S D I F F E R E N T I A T I O N
Squamous differentiation, defined by the presence of intercellular bridges or keratinisation, occurs in approximately 20-40% of urothelial carcinomas of the bladder. 5, 6, 23, 24 Its frequency increases with grade and stage ( Figure 1) . 23 Some cases have urothelial carcinoma in situ as the only urothelial component. Cases with areas of squamous differentiation may have a less favourable response to therapy than pure urothelial carcinoma, which seems to be related to a more advanced stage at presentation. [14] [15] [16] [17] [18] [19] [20] 25 Low-grade urothelial carcinoma with focal squamous differentiation has a higher recurrence rate than pure low-grade urothelial carcinoma. 23, 26 Tumours with any identifiable urothelial element are classified as urothelial carcinoma with squamous differentiation, and an estimate of the percentage of squamous component should be provided in the report. Urothelial carcinoma with squamous differentiation may express urothelial (S100P, 83%; GATA3, 35%; uroplakin II, 13%) and squamous associated markers (CK14, 87%; desmoglein-3, 70%). 27, 28 No specific markers exist to help with the distinction of squamous differentiation in urothelial carcinoma from pure squamous cell carcinoma, and the diagnosis relies on the clinical history and the absence of a clear-cut conventional urothelial carcinoma component upon histological analysis. 8 The limited available data support cluster squamous differentiation with the basal molecular subtype of urothelial carcinoma. Although human papillomavirus has been identified in a subset of these cases, it is generally not considered to be causative to the development of this variant of urothelial carcinoma.
Glandular differentiation is less common than squamous differentiation and may be present in approximately 6-18% of urothelial carcinomas of the bladder ( Figure 1) . 5, 24, [30] [31] [32] [33] Glandular differentiation is defined by the presence of true glandular spaces within the tumour. These may be tubular or enteric glands with mucin secretion. Rarely, a pattern with colloid-mucinous differentiation characterised by nests of cells 'floating' in extracellular mucin (occasionally with signet ring-like cells) may be seen. A form of glandular differentiation with villous-like appearance has been described associated with papillary urothelial carcinoma. 24, [30] [31] [32] [33] Urothelial carcinomas with glandular differentiation may be seen occasionally associated with urothelial carcinoma in situ with glandular differentiation. 34 Rarely, changes of M€ ullerian-like Pseudoglandular changes characterised by cytoplasmic MUC-containing cells are present in 14-63% of typical urothelial carcinoma and are not considered to represent glandular differentiation. The expression of MUC5AC-apomucin may be useful as an immunohistochemical marker of glandular differentiation in urothelial tumours. 31 The diagnosis of adenocarcinoma is reserved for pure tumours. As reported recently, TERT mutations may be seen in approximately 70% of urothelial carcinoma with glandular differentiation, but TERT mutations are consistently negative in primary adenocarcinoma of the bladder, a finding with implications in the differential diagnosis of glandular lesions of the bladder. 32 Although patients with squamous or glandular differentiation are more likely to present with advanced disease, when adjusted by stage patients with urothelial carcinoma with glandular differentiation had no survival differences with respect to conventional urothelial carcinoma or urothelial carcinoma with squamous differentiation.
U R O T H E L I A L C A R C I N O M A W I T H T R O P H O B L A S T I C D I F F E R E N T I A T I O N
Syncytiotrophoblastic giant cells are present in up to 28-35% of urothelial carcinoma cases, producing substantial amounts of immunoreactive beta-human chorionic gonadotrophin (bHCG) indicative of syncytiotrophoblastic differentiation ( Figure 1 ).
35-38
The number of bHCG-immunoreactive cells is associated with higher cancer grade and stage. Elevated secretion of bHCG into the serum may be associated with a poor response to radiation therapy and can be used in the follow-up of these patients. In patients with metastatic disease, the elevated secretion of bHCG into the serum has been linked with low response to chemotherapy [35] [36] [37] [38] The most important differential diagnostic consideration is choriocarcinoma, the diagnosis of which may require a high copy number of the isochromosome 12p, as seen by fluorescence in-situ hybridisation (FISH), thus supporting germ cell differentiation. 39 bHCG and other placental marker expressions in poorly differentiated urothelial carcinoma without overt syncytiotrophoblastic differentiation probably represent a metaplastic phenomenon. Early reported 'primary choriocarcinoma of the bladder' probably represent urothelial carcinoma with syncytiotrophoblasts. [35] [36] [37] [38] 
O T H E R U R O T H E L I A L C A R C I N O M A S W I T H D I V E R G E N T D I F F E R E N T I A T I O N
Small-cell carcinoma of the bladder often coexists with conventional urothelial carcinoma, squamous carcinoma and adenocarcinoma or sarcomatoid carcinoma ( Figure 1 ). Any amount of small-cell carcinoma should be reported, as this is relevant in guiding therapy. These tumours are now part of the neuroendocrine bladder tumour categories and are therefore managed as their most common counterpart in the lung. 1, [40] [41] [42] The diagnosis of small-cell carcinoma is based on the histology of the tumour, given the fact that some cases are negative for all immunohistochemical markers, and therefore the only criterion to ascertain the origin is finding a component of conventional urothelial carcinoma (Table 2 ). Even more rare is the finding of different lines of germ cell differentiation in an otherwise conventional urothelial carcinoma. 1 
Nested Urothelial Carcinoma
This variant of urothelial carcinoma was first described as a tumour with deceptively benign appearance resembling von Brunn nests ( Figure 2 , Table 4 ). A variable proportion of the infiltrating nests may exhibit small tubular lumens. The architectural growth pattern of the tumour varies from solid expansile to infiltrative nests, with nuclei of low to intermediate nuclear grade and occasional nuclear enlargement in deep aspects of the tumour. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] The definition of nested urothelial carcinoma has been expanded to include other tumours showing deceptively benign histology, such as the large nested carcinoma and the urothelial carcinoma with small tubules, earlier considered separate entities. 1, 43, 53 A component of conventional urothelial carcinoma is frequently present. The nested urothelial carcinoma, seen either in pure form or with a component of conventional urothelial carcinoma, has a poor outcome. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] The differential diagnosis of the nested variant of urothelial carcinoma includes lesions and tumours with nested-like morphology as prominent von Brunn nests, cystitis cystica, cystitis glandularis, inverted papilloma, nephrogenic metaplasia, carcinoid tumour, paraganglionic tissue and paraganglioma (Table 4) . [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] The large nested variant of urothelial carcinoma seems to be inter-related to urothelial carcinoma with inverted growth, and the differential between both entities might not always be possible. 54 Recently, it has been reported as a nested-like morphology associated with serous ovarian carcinoma mimicking a nested variant of urothelial carcinoma that might represent a diagnostic pitfall in practice. 55 The nested urothelial carcinoma is linked with advanced tumour stage and nodal invasion which may reflect, in part, the late diagnosis frequently associated with this tumour. 56 Nested carcinoma shares similar immunohistochemical features and clinical outcomes as conventional urothelial carcinoma, with no difference in recurrence rate or survival when treated surgically. 43, 52, 56 Nested urothelial carcinoma may be distinguished from benign mimickers by the presence of TERT promoter mutation associated with this tumour.
50,51

Microcystic Urothelial Carcinoma
Microcystic carcinoma is a variant of urothelial carcinoma with a deceptively benign appearance showing microcysts, macrocysts or tubular structures, with cysts ranging from microscopic to 2 mm in diameter ( Figure 3) . 57, 58 The cysts are round-oval and of varying sizes; the periphery of large cysts are frequently punctuated by many smaller cysts (Figure 3) . 57, 58 The cysts are lined by urothelial, low columnar cells, or by a single layer of flattened epithelium of low-intermediate nuclear grade. Focal high-grade conventional urothelial carcinoma may be present in approximately 40% of cases. There are no survival differences for microcystic carcinoma compared to conventional urothelial carcinoma. 57 Differential diagnosis includes benign proliferations such as florid polypoid cystitis cystica and glandularis and adenocarcinoma. Rarely, a microcystic variant Microcystic urothelial carcinoma may be distinguished from benign mimickers by the presence of TERT promoter mutation associated with this tumour. 50 
Micropapillary Urothelial Carcinoma
Micropapillary urothelial carcinoma resembles papillary serous carcinoma of the ovary. It is a variant of urothelial carcinoma with male predominance (mean age = 66 years), poor prognosis, frequent lymph node metastases and low survival rates, despite therapy. 59, 60 Micropapillary carcinoma is frequently admixed with conventional urothelial carcinoma or other variant histology.
Some studies suggest that prognosis is related to the proportion of the micropapillary component, a concept that remains controversial. [59] [60] [61] [62] [63] [64] [65] [66] Similarly, cases with a moderate or extensive micropapillary component are at high risk of having advanced stage at presentation.
Conversely, cases with surface micropapillary and less than 10% micropapillary have a high chance of detection at an early stage (Figure 4) . 61 One important issue concerning this variant of urothelial carcinoma is the use of 'micropapillary' terminology to describe non-muscle invasive bladder carcinoma (NMIBC). For instance, NMIBC with micropapillary morphology is not necessarily associated with worse outcomes compared with conventional NMIBC. 60, 64 Therefore, caution is warranted in interpreting a diagnosis of NMIBC or in situ micropapillary carcinoma. In fact, it is now recognised that a micropapillary-like architecture may be seen in NMIBC and urothelial carcinoma in situ; therefore, if the micropapillary component is limited to the non-invasive component, the tumour should not be classified as micropapillary carcinoma. 1, [59] [60] [61] [62] [63] [64] [65] [66] [67] Some studies have observed that intravesical therapy is ineffective for micropapillary variant disease and suggested cystectomy, even in T1 patients with bacillus Calmette-Gu erin-responsive disease. However, other data suggest that a more standard bladder sparing approach is reasonable in select NMIBC patients. At present, it is better to rely upon the currently approved urological guidelines when counselling patients on issues related to the controversial area of NMIBC with micropapillary features. [59] [60] [61] [62] [63] [64] [65] [66] [67] Micropapillary carcinoma is composed of infiltrating slender delicate filiform processes or small tight papillary tumour cell clusters that lie within lacunae. True vascular and lymphatic invasion is commonly demonstrable, and most cases show invasion of the muscularis propria or deeper (Figure 4) . Interobserver reproducibility for a diagnosis of invasive micropapillary carcinoma remains moderate (kappa = 0.54), with 93% agreement between dedicated uropathologists. Multiple nests within the same lacunar space and tumour rings had the highest association with a diagnosis of invasive micropapillary carcinoma. 62 Expression of keratins by tumour cells of micropapillary carcinoma is similar to that of typical urothelial carcinoma, but micropapillary carcinomas are much more likely to express CA125. MUC1 expression is seen in the stroma-facing aspect of the tumour cell groups, indicating a reversal of the normal cell orientation in the tumour.
Carcinomas with micropapillary histology have also been reported in the lung, breast, pancreas, colorectum and salivary glands. Clinical correlation is usually required, but a CK7 + , CK20 + and uroplakin III + immunopanel would favour bladder primary. Micropapillary urothelial carcinoma usually expresses FoxA1, a marker of luminal phenotype. [59] [60] [61] [62] [63] [64] [65] [66] This luminal subtype appears as a dominant trait, such that even urothelial carcinoma with small regions of micropapillary growth shares this subtype. Luminal tumours may have wild-type p53, and can be resistant to chemotherapy. 12 ERBB2 (HER2) amplification by FISH technology is observed more frequently in micropapillary urothelial carcinoma than in conventional urothelial carcinoma. These patients have worse cancer-specific survival. It also provides a potential role for ERBB2-targeted therapy. 65, 66, [68] [69] [70] 110 
Lymphoepithelioma-Like Urothelial Carcinoma
This variant resembles lymphoepithelioma of the nasopharynx and has been described in the urinary bladder and the urinary tract. [71] [72] [73] [74] [75] Lymphoepithelioma is seen in men with haematuria (mean age = 69 years). Tumours may be pure or mixed, with conventional urothelial carcinoma exhibiting glandular or squamous differentiation. [71] [72] [73] [74] [75] The epithelial component is composed of nests, sheets and cords of undifferentiated cells with large pleomorphic nuclei and prominent nucleoli ( Figure 5 ). The cytoplasmic borders are poorly defined, imparting a syncytial appearance, with positive CK AE1/AE3, CK7, GATA3 and negative-rare CK20. The prominent lymphoid stroma includes T and B lymphocytes, plasma cells, histiocytes and occasional neutrophils or eosinophils. CD3 T lymphocytes predominate. 67, [71] [72] [73] [74] [75] Lymphoepithelioma cases have frequent p53 accumulations, supporting a similar pathogenesis to urothelial carcinoma. Epstein-Barr virus or human papillomavirus infection has not been identified in lymphoepithelioma-like carcinoma of the bladder. 72 The major differential diagnostic considerations are poorly differentiated urothelial carcinoma with lymphoid inflammatory response, poorly differentiated squamous cell carcinoma and lymphoma. Lymphoepithelioma-like bladder carcinoma has been found to have a similar prognosis, chemosensitivity and response to immunotherapy to that observed in conventional urothelial carcinoma. In its pure form, this variant appears to have a good prognosis with low metastatic potential, and patients may do well when treated with chemotherapy alone. Recent preliminary data support using immunotherapy in these patients.
67,71-75
Plasmacytoid/Signet Ring Cell/Diffuse Urothelial Carcinoma
The plasmacytoid carcinoma variant of urothelial carcinoma is rare and aggressive, and is characterised by the presence of discohesive individual cells that resemble plasma cells ( Figure 6 ). [76] [77] [78] [79] [80] [81] In addition to the plasmacytoid morphology, a number of single cells with cytoplasmic vacuoles, with or without mucin, which impart a signet ring cell appearance, are typically present ( Figure 6 ). 1 These tumours are not associated with any extracellular mucin production, a useful parameter to differentiate plasmacytoid carcinoma from adenocarcinoma with signet ring cells, which is associated with extracellular mucin. The pattern of growth for plasmacytoid carcinoma is typically solid expansile nests or alveolar structures with discohesive cells; myxoid pattern can be present rarely. Extreme discohesive growth patterns mimicking infiltrating lobular carcinoma of the breast and diffuse carcinoma of the stomach have been described. Half of reported cases also showed conventional urothelial carcinoma or urothelial carcinoma in situ.
76-81
The urothelial nature of the proliferating cells can be confirmed by immunostains for the urothelial lineage markers CK7, CK20, p63, GATA3 and uroplakin III. CD138 (plasma cells marker) is positive in onethird of cases. Artefactual expression of kappa light chains has been seen focally is some cases, a further confounding factor. MUM1 is consistently negative in all cases. GATA3 is positive in plasmacytoid variant of urothelial carcinoma and negative in diffuse adenocarcinoma of the stomach.
The patients typically present at an advanced stage with a high relapse and mortality rate, and with frequent peritoneal carcinomatosis. Plasmacytoid carcinoma appears to be chemotherapy responsive. [76] [77] [78] [79] [80] [81] Loss of E-cadherin, encoded by the CDH1gene, has been described recently in a large cohort of patients with plasmacytoid urothelial carcinoma and may account for the marked discohesion of these malignant cells. Loss of E-cadherin protein by immunohistochemistry may be seen in approximately 70% of plasmacytoid carcinomas, in contrast to only 11% of conventional urothelial carcinomas. CDH1 mutations have been described in 87% of plasmacytoid carcinomas, whereas no CDH1 mutations were seen in conventional urothelial carcinomas. 80 Some cases show CDH1 methylation instead of mutation. 80 The differential diagnostic considerations include lymphoid reactions, lymphoma, multiple myeloma, urothelial carcinoma with rhabdoid features, signet ring cell-diffuse adenocarcinoma, paraganglioma, neuroendocrine carcinoma, melanoma and rhabdomyosarcoma.
11,76-86
Sarcomatoid Urothelial Carcinoma
Sarcomatoid urothelial carcinoma frequently presents as advanced disease and has a poor outcome. 11, [82] [83] [84] [85] [86] Pathological stage seems to be the best predictor of survival in sarcomatoid carcinoma. 82 The term 'sarcomatoid carcinoma' applies when a malignant neoplasm exhibits morphological or immunohistochemical evidence of both epithelial and mesenchymal differentiation. Heterologous elements may be present, and should be acknowledged in the pathology report. A small subset of sarcomatoid carcinomas may have a prominent myxoid stroma. 11, [82] [83] [84] [85] [86] Sarcomatoid carcinomas seem to be the common final pathway of all forms of epithelial bladder tumours, a hypothesis supported by molecular data and morphological evidence. 84 The mesenchymal component observed most frequently is an undifferentiated high-grade spindle cell sarcoma. The most common heterologous element is osteosarcoma, followed by chondrosarcoma, rhabdomyosarcoma, leiomyosarcoma, liposarcoma, angiosarcoma and multiple types of mesenchymal differentiation. 11, [82] [83] [84] [85] [86] The rare adenosarcoma of the bladder may also enter differential diagnosis with sarcomatoid carcinoma. 86 Cytokeratin immunostaining may be helpful in this setting, but pathologists should bear in mind that focal cytokeratin immunoreactivity may be seen in smooth muscle tumours and inflammatory myofibroblastic proliferations. Sarcomatoid urothelial carcinoma also shows positive expression of GATA3 and PAX8, at least focally, but GATA3 is negative in sarcomatoid carcinoma of the kidney (Table 5) .
Sarcomatoid carcinoma with prominent myxoid and sclerosing stroma may be mistaken for Figure 5 ). 11, [82] [83] [84] [85] [86] One recent study has shown that markers representative of epithelial-mesenchymal transition, including vimentin, FoxC2, SNAIL and ZEB1, are often overexpressed in sarcomatoid urothelial carcinoma. Concurrent loss of E-cadherin and elevated N-cadherin expressions is also evident in most cases. 83 A recent report found TERT C228T mutations in 35% of sarcomatoid carcinomas. All patients with TERT mutation died of cancer within 2 years after surgery.
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Giant Cell Urothelial Carcinoma
Pleomorphic giant cell carcinoma is a rare and aggressive form of bladder cancer recognised by the current WHO classification of tumours of the urinary tract.
1 It is associated with poor prognosis and presents at an advanced stage. 87 The architectural pattern of growth varied from infiltrating pleomorphic tumour with bizarre giant cells to solid expansile nests with occasionally discohesive cells ( Figure 6) . A rare hypocellular sclerosing pattern may also be recognised. The proliferating anaplastic cells are giant and bizarre and occasionally multinucleated, with frequent typical or atypical mitoses. 87 Most reported cases had concurrent conventional urothelial carcinoma. Similarly, occasional cases may be composed purely of these pleomorphic giant cells, raising a differential diagnosis of a secondary carcinoma involving the bladder. Giant cell carcinoma of lung should be considered. 
Lipid-Rich Urothelial Carcinoma
The lipid-rich variant is a urothelial carcinoma which exhibits a lipoblast-like cell type resembling liposarcoma, with eccentrically placed nucleus and abundant vacuolated cytoplasm ( Figure 5) . 88, 89 Lipid-rich carcinomas are seen in association with conventional urothelial carcinoma and may be seen admixed with other variants. Immunohistochemical staining of lipidrich carcinoma is consistent with urothelial origin, and electron microscopy analysis supports lipid content of the cells. 88 A recent study based on 27 patients confirmed an identical pattern of loss of heterozygosity between areas of conventional urothelial carcinoma and the lipid-rich component, thus suggesting a common clonal origin. 88 Limited data suggest that this variant may be associated with worse outcomes, as most cases present at an advanced stage. 88, 89 Clear Cell (Glycogen-Rich) Urothelial Carcinoma
Up to two-thirds of urothelial carcinoma cases have foci of clear cell change resulting from abundant cytoplasmic glycogen, which can be confirmed by periodic acid-Schiff stain which is sensitive to diastase digestion ( Figure 6) . 30, 90 The glycogen-rich clear cell variant of urothelial carcinoma consists predominantly or exclusively of cells with abundant clear cytoplasm and appears to represent the extreme end of the morphological spectrum of tumour with cytoplasmic clearing. Tumour cells show positive immunostaining for CK7, p63 and GATA3, which supports urothelial origin. In most cases there is recognisable conventional urothelial carcinoma admixed, a finding that helps in the diagnosis. Preliminary data suggest that this variant may be associated with worse outcomes, as most cases present at an advanced stage. 30, 90 Recognition of this pattern avoids confusion with clear cell M€ ullerian adenocarcinoma of the bladder and metastatic clear cell carcinoma from the kidney or prostate, or with PEComa arising in the bladder. 91 Cytoplasmic clearing as a result of thermal artefact in transurethral resections should not be mistaken for this variant of bladder cancer.
30,90
Poorly Differentiated Urothelial Tumours
This category represents a new entry in the current WHO classification of the urinary tract tumours. 1 Poorly differentiated tumours span a spectrum that includes tumours with mixed morphologies such as small-cell carcinoma, sarcomatoid carcinoma, giant cell carcinoma, undifferentiated carcinoma not otherwise specified (NOS) and the so called osteoclast-rich undifferentiated carcinoma. 1, 92, 93 All the poorly differentiated carcinomas may be associated with conventional urothelial carcinoma or other forms of divergent differentiation, including glandular, trophoblastic or squamous differentiation, or with combinations of poorly differentiated patterns. Limited reported data support a poor outcome to this category of poorly differentiated urothelial tumour, with multiple histological patterns at time of first diagnosis. 1, 92, 93 This subtype of urothelial carcinoma is considered a poorly defined entity and might be better considered a de-differentiated urothelial carcinoma.
Histological Variations of Urothelial Carcinoma
The morphological plasticity observed in urothelial carcinoma explains not only the well-characterised variants of urothelial carcinoma, as presented above, but also some morphological patterns of growth known as 'variations' of conventional urothelial carcinoma. 1, 92, 93 Awareness of these variations can help to avoid unnecessary work-up in these patients. A brief summary concerning the main variations of urothelial carcinoma follows.
U R O T H E L I A L C A R C I N O M A W I T H I N V E R T E D G R O W T H
The relevance of this pattern of growth is due to the potential for misinterpretation of urothelial carcinoma with inverted growth as benign inverted papilloma (Table 6) . [94] [95] [96] The inverted variant of urothelial carcinoma demonstrates variable nuclear pleomorphism, architectural abnormality and increased mitotic activity -helpful clues to diagnosis (Figure 7 ). Immunohistochemistry may also help to differentiate carcinoma with inverted growth from inverted papilloma (Table 6 ). Whereas inverted papilloma usually does not demonstrate immunoreactivity for Ki-67, p53 or CK20, urothelial carcinomas with inverted growth pattern frequently express one or more of these biomarkers. Similarly, inverted papilloma does not show the molecular features of urothelial carcinoma on UroVysion FISH analysis, whereas inverted-pattern urothelial carcinomas often demonstrate genetic alterations that are commonly seen in bladder cancer. [94] [95] [96] TERT mutation are typically present in urothelial carcinoma with inverted growth, and may be seen only rarely in inverted papilloma. Tumours with prominent endophytic growth may appear to invade the lamina propria with a pushing border, which explains the low aggressiveness associated with inverted urothelial carcinoma ( Table 6 ). [94] [95] [96] Inverted growth has been described in papillary urothelial neoplasms of low malignant potential and in low-and high-grade urothelial carcinomas.
U R O T H E L I A L C A R C I N O M A I N S P E C I F I C C L I N I C A L S E T T I N G
Bladder augmentation cystoplasty Relevant in bladder augmentation is the appearance of primary or recurrent urinary bladder cancers including carcinoma in situ. Virtually all variants of urothelial carcinoma can be seen in bladder augmentation. Some cases may present as lymphovascular or perineural invasion. 97 
Neuropathic bladder
In neuropathic bladder, most pathological findings are related to the high frequency of bladder infections; therefore, cystitis may be seen in these patients. Additional changes may be seen related to long-term catheter drainage. Keratinising squamous metaplasia is an important premalignant lesion predisposing to development of squamous cell carcinoma.
Children and young adults
Urothelial neoplasms in children and young adult patients are rare, and hypothesised to have a lower rate of recurrence and progression than those of older adults. Because of their rarity, data regarding clinical, pathological and molecular abnormalities in these tumours are limited. Most cases reported are low-grade papillary urothelial carcinoma, high-grade papillary urothelial carcinoma, urothelial papilloma or papillary urothelial neoplasm of low malignant potential. 98 Recent molecular analysis demonstrated rare, if any, FGFR3 or TP53 mutation. Chromosomal abnormalities were detected only in a minor number of patients ≥19 years of age (seen in low-and highgrade urothelial carcinomas). No tumour showed molecular abnormalities in patients <19 years of age. In contrast, chromosomal abnormalities detected by UroVysion FISH are sometimes present in patients >19 years of age, a finding in support of the recently proposed hypothesis that an age of 19-20 years separates distinct molecular pathways of urothelial carcinogenesis. 98 Bladder diverticulum Approximately half of all invasive carcinomas are urothelial. The remainder consists of uncommon subtypes, including small-cell carcinoma, squamous cell carcinoma and adenocarcinoma. Approximately half of all cases contain non-invasive, low-or high-grade urothelial carcinoma. Virtually all variants of urothelial carcinoma may be seen in bladder diverticula. Pathological stage is the most important prognostic factor. No pT2 stage can be assigned in acquired diverticula because there is no detrusor muscle layer.
Infiltrating urothelial carcinoma may be associated with a variety of stromal reactions, which are occasionally pronounced. [98] [99] [100] The pseudosarcomatous stroma rarely displays sufficient cellularity, cytological atypia, spindle cell proliferation or myxoid appearance to raise serious concern for sarcomatoid carcinoma.
Other tumours may present with associated stromal osseous and chondroid metaplasia which may be seen in primary urothelial carcinoma and its metastases. [98] [99] [100] Benign-appearing osteoclast-like CD68 + giant cells may rarely be seen in the stroma of a urothelial carcinoma, a feature of unknown significance.
An inflammatory cell response in the stroma adjacent to the invasive tumours is relatively common. This response usually takes the form of a lymphocytic infiltrate with a variable admixture of plasma cells, neutrophils and occasionally eosinophils, a finding which is viewed as indicative of a good prognosis.
98-100
New Entities Of Bladder Cancer
A brief summary of recently proposed variants of urothelial carcinoma not currently included in the WHO classification of urinary tract tumours follows.
P S E U D O A N G I O S A R C O M A T O U S V A R I A N T O F U R O T H E L I A L C A R C I N O M A
The pseudoangiosarcomatous pattern is unique for its histological resemblance to angiosarcoma (Figure 7) . It is seen more frequently in males with poor outcome (age range = 47-87 years). 101 Pseudoangiosarcomatous carcinoma may be associated with conventional urothelial carcinoma with divergent differentiation, sarcomatoid carcinoma, small-cell carcinoma and micropapillary carcinoma. Histologically, the pseudoangiosarcomatous carcinomas are characterised by tumour cell discohesion (acantholytic) that creates pseudolumina formations surrounded by attached residual tumour cells. The tumour is frequently associated with a dense variable collagenic matrix. The tumour cells show positive immunostaining for p40, CK7 and GATA3, supporting urothelial origin. 101 
U R O T H E L I A L C A R C I N O M A W I T H M Y X O I D S T R O M A ( C H O R D O I D -L I K E )
This is a recently described entity with extensive mucinous myxoid stroma and chordoid-like appearance with prominent cellular cording in a myxoid matrix, a pattern that may resemble extraskeletal myxoid chondrosarcoma, chordoma or yolk sac tumour (Figure 7) . 102 These carcinomas usually present with high-stage disease, but maintain an immunophenotype of urothelial lineage. The tumour may be seen in both males and females at a mean age of 68 years. All cases present concurrent conventional urothelial carcinoma, at least focally. This finding, together with the reported positivity with antibodies to p63 and 34BE12, is helpful in the differential diagnosis with adenocarcinoma. Aggressiveness seems to be related to stage at diagnosis. 102 Ultrastructural analysis supports mucin production by cancer cells.
U N D I F F E R E N T I A T E D C A R C I N O M A
Similar to other organs, undifferentiated bladder carcinoma shows three different morphological expressions: undifferentiated carcinomas of the bladder with rhabdoid features, undifferentiated carcinoma NOS and osteoclast-rich undifferentiated carcinoma (Figure 7) . 92, 93, 104, 105, 106 A rare and aggressive disease, undifferentiated carcinoma NOS of the urinary bladder refers to carcinomas that are composed of sheets or isolated undifferentiated cells with no specific pattern of differentiation identifying it as urothelial, squamous, adenocarcinoma or any other recognised category of bladder carcinoma. 92 Immunohistochemical staining demonstrates positivity, at least focally, with cytokeratin. Some cases may focally express uroplakin III, but these cases are consistently negative for other lineage markers such as a-fetoprotein, bHCG, PSA, vimentin, and neuroendocrine markers. Limited reported data suggest an aggressive variant of urothelial carcinoma that presents at an advanced stage. 92 Some undifferentiated carcinomas of the bladder may rarely present rhabdoid features, frequently characterised by complete loss of at least one SWI/ SNF (chromatin remodelling complex) subunit detected in 70%. SMARCA2 is most frequently lost followed by ARID1A, SMARCB1/INI1, SMARCA4 and SMARCC1 (Table 2) . 104 Limited experience to date suggests these are aggressive neoplasms (Figure 7) . 104, 105 A rare case of urinary bladder myoepithelioma has been described in a long-term survivor of atypical teratoid rhabdoid tumour with a germline SMARCB1 mutation. 107 Osteoclast-rich undifferentiated carcinomas are rare tumours that have been reported in many organs, including the urinary bladder. The tumours are composed of mononuclear cells, variably positive for epithelial markers and GATA3 (95%) but negative for uroplakin II, with a spectrum of atypia, including marked pleomorphism and reactive osteoclast-like CD68 + giant cells. Recognisable conventional urothelial carcinoma or urothelial carcinoma in situ is invariably present in most cases, at least focally. Cases described in the literature tend to show poor outcomes ( Figure 7) . 93, 106 Occasionally, an undifferentiated carcinoma may be seen with focal conventional urothelial carcinoma, a finding useful in the final characterisation of the neoplasia together with the finding of urothelial lineage by immunohistochemistry using GATA3 or S100P.
M I X E D E P I T H E L I A L A N D S T R O M A L T U M O U R S O F T H E B L A D D E R
M€ ullerian adenosarcoma M€ ullerian adenosarcoma is a biphasic neoplasm occurring most commonly in the uterus and less frequently in an ovary. Rarely, it has been described to occur in other sites, such as peritoneum and liver. Like its uterine counterpart, M€ ullerian adenosarcoma is a lowgrade tumour with tendency to recur. A unique case has been reported recently in a 62-year-old woman with a long-standing history of endometriosis, a fact that suggests a pathogenic link. 86 Light microscopy showed a biphasic epithelial and stromal tumour with benign-appearing glands surrounded by densely cellular endometrial-type stroma that is densely cellular with increased mitotic figures. The stroma surrounding the glands was more cellular than the intervening areas, which were more loose and oedematous. 86 Immunohistochemistry staining revealed positive staining for PAX2/8 within the glands, for positive CD10 and WT1 within the spindle cell stroma and for oestrogen and progesterone receptors in both. Staining for desmin, GATA3, p63 and human papillomavirus was negative. Molecular analyses identified mutations in protein kinase B E17K, tyrosine kinase 3 D835N, KRAS protooncogene, GTPase G12D and HRAS protooncogene, GTPase G12S. 86 Phyllodes tumour Phyllodes tumours of the male urogenital tract are rare, arising mainly in the prostate or seminal vesicles. A unique primary urinary bladder phyllodes tumour has been described recently in a 54-year-old man who underwent partial cystectomy for a recurrent bladder tumour. 108 The patient presented with haematuria and multiple episodes of recurrence. Histological sections showed a polypoid epithelial tumour arising from the mucosal compartment and arranged in broad-based papillae, many of which exhibited a club-shaped or cloverleaf-type appearance and clefting. Subepithelial condensation of stromal cells was noted. The stromal cells were spindled and stellate in appearance, did not show conspicuous cytological atypia, and mitotic figures were not identified. The overall appearance was felt to be in keeping with a phyllodes tumour of the urinary bladder, low-grade/ benign. The patient had an uneventful postoperative course with no evidence of recurrence. 108 The authors suggest that in view of the potential for local recurrence that phyllodes tumours exhibit at other sites, complete surgical resection and close clinical and radiological follow-up were advisable.
Variant Urothelial Carcinoma in Clinical Practice
Current literature provides increasingly valuable data on the clinical significance and therapy-related issues concerning urothelial carcinoma with variant histology compared to conventional urothelial carcinoma. In general, variant urothelial carcinoma is considered an aggressive feature as it worsens overall survival due to a higher rate of upstaging after surgery. [13] [14] [15] [16] [17] [18] [19] [20] 25, 37, 38, 56, 67, [109] [110] [111] [112] Gofrit et al. suggest that a patient with variant bladder cancer treated with intravesical immunotherapy has a 27% chance of dying from this disease within 5 years when compared to a 7.5% chance for a patient with conventional high-grade urothelial carcinoma. 20 Cohen et al. recommend considering aggressive treatment for bladder cancer with variant histology when identified. 19 Similar to that observed in conventional urothelial carcinoma, the study of Krasnow et al. suggests that variant urothelial carcinoma responded to trimodality bladder-sparing therapy, and there was no significant difference in complete response, overall survival, disease-specific mortality or salvage cystectomy rates compared with conventional urothelial carcinoma. 14 Lin et al. supports the use of neoadjuvant chemotherapy in patients with mixed histology given the significantly higher rate of pT0 at final pathology, and therefore strong consideration should be given to the use of neoadjuvant chemotherapy in the treatment of mixed histology muscle invasive bladder cancer patients. 17 However, Pokuri et al.
recently observed that the presence of pure urothelial carcinoma favoured a pT0 response to neoadjuvant chemotherapy compared to those with variant histological features or mixed tumours. 18 Overall, most studies on histological variants of bladder cancer suggest a more aggressive clinical course than conventional urothelial carcinoma, but conclusive data on their effect on survival are currently lacking.
Conclusion
Current diagnosis of variant histology in urothelial carcinoma substantially informs patient care and provides a novel framework to stratify patients according to potential response to a given therapy. Molecular alterations, particularly new molecular classifiers, which characterise some of the variants of urothelial carcinoma, might become targets for novel drugs to improve the overall response of these patients. However, future studies are needed to understand more clearly the diagnostic criteria to be applied in the correct diagnosis of these entities.
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